Explore evidence

26,394,425 CFA_francsDrugs accounted for 26,394,425 CFA francs (40,235.4 €).

Gabonpaludismeobserved 2018–2019published 2021Malaria journalPubMeddocument of 9 observations

53.7 %La prévalence du multiplicity of infection (MOI) > 1 chez les enfants uniquement positifs pour P. falciparum était de 53,7 % dans le groupe non-APOE Ɛ4 (72 sur 134).

GabonpaludismeHAL · Unilimdocument of 81 observations

100 %Five of the five (100%) nonimmune European controls with normal hemoglobin developed parasitemia by thick blood smear.

Gabonpaludismepublished 2018The American journal of tropical medicine and hygieneeurope_pmcdocument of 12 observations

375 parasites/μLChez les enfants gabonais porteurs de l’allèle APOE Ɛ4 et du phénotype HbAS, la densité parasitaire asexuée médiane était de 375 parasites/μL pour Plasmodium spp.

Gabonpaludismeobserved October 2013HAL · Unilimdocument of 81 observations

5.1 %Respiratory distress was observed in 5.1% of severe malaria cases.

Gabonpaludismeobserved 2019published 2023BMC Infectious DiseasesOpenAlexdocument of 14 observationsDOI 10.1186/s12879-023-08133-y

0 %The prevalence of pfhrp2 single deletions was 0% in the Republic of Congo.

Gabonpaludismepublished 2023Pathogens (Basel, Switzerland)europe_pmcdocument of 9 observationsDOI 10.3390/pathogens12030455

41 hoursThe afebrile time interval between fever peaks shortened progressively from 41 to 31 hours in patients undergoing malaria fever therapy.

Gabonpaludismepublished 2025The American journal of tropical medicine and hygienePubMeddocument of 6 observations

98 %98% of asymptomatic infections were caused by Plasmodium falciparum.

Gabonpaludismepublished 2024Acta parasitologicaeurope_pmcdocument of 4 observationsDOI 10.1007/s11686-023-00783-x

20.5 %Mixed genotypes were found at codon 59 in 20.5% of the Plasmodium falciparum isolates from HIV-infected adults in Gabon.

Gabonpaludismeobserved 2015–2016published 2019Malaria research and treatmenteurope_pmcdocument of 7 observationsDOI 10.1155/2019/9523259

845,880 parasites/µLThe initial parasite density was as high as 845,880 parasites/µL.

Gabonpaludismepublished 2024International journal of infectious diseases : IJID : official publication of the InternatPubMeddocument of 3 observations

6 patientsTreatment with artesunate-fosmidomycin was associated with transient grade I neutropenia (absolute neutrophil counts of 750 to 1,200/μL) in six patients.

Gabonpaludismepublished 2005Antimicrobial agents and chemotherapyeurope_pmcdocument of 6 observations

3.6 %The chloroquine-sensitive pfcrt haplotype CVMNK increased from 3.6% in 2009 to 98.2% in 2024 in Lambaréné, Gabon.

Gabonpaludismeobserved 2009published 2026International journal of molecular scienceseurope_pmcdocument of 6 observations

3.85 aORRespiratory distress was identified as an independent predictor of fatal outcome in severe malaria with adjusted odds ratio 3.85.

Gabonpaludismepublished 2023Malaria JournalOpenAlexdocument of 25 observationsDOI 10.1186/s12936-023-04512-7

35 %In 17 out of 48 individuals (35%), all pfmsp1 genotypes identified during the assessed period were detected at baseline.

Gabonpaludismepublished 2024International journal of infectious diseases : IJID : official publication of the Internateurope_pmcdocument of 4 observations

95.5 %At day 28, the PCR-adjusted efficacy of artemether-lumefantrine was 95.5%.

Gabonpaludismepublished 2011PLoS medicineeurope_pmcdocument of 15 observations

3.26 mmol/LSerum lipid levels were significantly lower in malaria patients compared with those with other febrile diseases: total cholesterol = 3.26 mmol/L (standard deviation = 0.94) versus 3.97 mmol/L (standard deviation = 1.22).

Gabonother febrile diseases · paludismepublished 2017The American journal of tropical medicine and hygieneeurope_pmcdocument of 3 observations

83.6 %83.6% of mothers interviewed in Franceville, southern Gabon, used an insecticide-treated net as a means of protection against malaria.

Gabonpaludismepublished 2023Malaria JournalOpenAlexdocument of 5 observationsDOI 10.1186/s12936-023-04584-5

8,560 episodesPatients experienced 8,560 malaria episodes.

Gabonpaludismepublished 2021PLoS medicineeurope_pmcdocument of 8 observationsDOI 10.1371/journal.pmed.1003669

27 %During a period of one year, 27% of the 497 afebrile males screened had positive rapid diagnostic test results for Plasmodium falciparum in villages near Lambaréné, Gabon.

Gabonpaludismeobserved one yearpublished 2007The American journal of tropical medicine and hygieneeurope_pmcdocument of 4 observationsDOI 10.4269/ajtmh.2007.77.939

54 %Anopheles gambiae s.s. showed 54% mortality to bendiocarb.

Gabonpaludismeobserved 2019published 2020Wellcome open researcheurope_pmcdocument of 8 observations

1.31 odds_ratioIn a cross-sectional survey conducted in Gabon between 2015 and 2016, the adjusted odds ratio for malaria and loiasis was 1.31 (95% CI: 0.81 to 2.11; p = 0.276).

Gabonloase · paludismeobserved 2015-2016published 2026Tropical medicine and infectious diseaseeurope_pmcdocument of 4 observations

23 %In this study, 23% of the 145 parturient women in Lambaréné, Gabon, were positive for Plasmodium falciparum by real-time polymerase chain reaction at delivery.

Gabonpaludismepublished 2006The American journal of tropical medicine and hygieneeurope_pmcdocument of 7 observationsDOI 10.4269/ajtmh.2006.75.798

15.3 %The overall prevalence of asymptomatic Plasmodium falciparum infection among 1,496 participants was 15.3%.

Gabonpaludismeobserved 2023published 2025Malaria journaleurope_pmcdocument of 3 observations

1 %In a repeated cross-sectional study during the 2023 rainy season, microscopy identified three Plasmodium vivax infections among 293 asymptomatic individuals in four riverine communities in Putumayo canton, Ecuador, corresponding to a prevalence of 1.0%.

Gabonpaludismeobserved 2023 rainy seasonpublished 2025Malaria journalPubMeddocument of 4 observations

58.6 %Prostration was present in 58.6% of severe malaria cases on admission.

Gabonpaludismepublished 2023Malaria journaleurope_pmcdocument of 25 observationsDOI 10.1186/s12936-023-04512-7